	US 11,744,843 B2
	Identification and treatment of T-cell epitopes of short H2A oncohistones
Jay Francis Sarthy, Seattle, WA (US); Antoine Molaro, Clermont-Ferrand (FR); Marie Bleakley, Seattle, WA (US); and Guo-Liang Chew, Singapore (SG)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed by Fred Hutchinson Cancer Research Center, Seattle, WA (US)
Filed on Nov. 1, 2021, as Appl. No. 17/516,600.
Claims priority of provisional application 63/108,217, filed on Oct. 30, 2020.
Prior Publication US 2022/0133760 A1, May 5, 2022
Int. Cl. A61K 31/704 (2006.01); A61K 31/136 (2006.01); A61P 35/00 (2006.01); C12Q 1/6886 (2018.01)

CPC A61K 31/704 (2013.01) [A61K 31/136 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)]

17 Claims

1. A method for treating a subject with lymphoma, the method comprising:

(a) collecting a sample from a subject having or suspected of having lymphoma;

(b) detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject;

(c) administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable,

wherein the anthracycline agent is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, and aclarubicin.